-
2022-502193-16-00
5
2023-11-14
Chronic lymphocytic leukemia, Multiple Myeloma and Non-Hodgkin Lymphom
-
2022-500699-76-00
5
2023-05-18
Active Systemic Lupus Erythematosus (SLE)
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2023-504931-42-00
4
2021-04-06
Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters tran
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2024-520108-25-00
4
2025-11-05
Non-small cell lung cancer (NSCLC)
-
2024-520050-38-00
5
2025-09-18
Extensive stage small cell lung cancer (ES-SCLC). S
-
2024-519773-19-00
5
2025-07-31
Gastroesophageal Junction Adenocarcinoma
-
2024-513621-23-00
5
2025-04-18
Advanced/metastatic non-small cell lung cancer (NSCLC)
-
2022-501483-18-00
10
2025-03-28
Advanced Non-Small Cell Lung Cancer
-
2024-515740-23-00
5
2025-03-25
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-513160-25-00
5
2024-10-30
Melanoma and Non-small-cell lung cancer
-
2023-503692-24-00
5
2024-09-25
Cutaneous Lupus Erythematosus
-
2023-508219-21-00
5
2024-09-12
BTC - Biliary Tract Cancer
-
2024-510965-41-00
5
2024-09-03
Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
-
2023-510178-15-00
5
2024-07-31
High-risk Large B-cell Lymphoma
-
2023-508359-38-00
5
2024-06-05
Early-stage Non-squamous Non-small Cell Lung Cancer
-
2023-506906-38-00
5
2024-05-23
Follicular Lymphoma
-
2023-507448-36-00
5
2024-02-16
Non-small Cell Lung Cancer
-
2023-503288-40-00
5
2024-01-26
Unresectable or Metastatic Melanoma
-
2023-506139-13-00
5
2024-01-04
Treatment naïve patients with MF
-
2023-505976-31-00
5
2023-11-24
Systemic Sclerosis (SSc) presenting with Limited or Diffuse Cutaneous